MindMed provides updates on two of its research initiatives, in partnership with the Liechti Lab (Switzerland).
MindMed provides updates on two of its research initiatives, in partnership with the Liechti Lab (Switzerland).
Levitee Labs announces that its shares are now eligible for clearing through the DTC.
Novamind announces that its shares are now eligible for electronic clearing through the DTC.
Recent market clues are suggesting that a much overdue rally for psychedelic stocks may be about to begin.
Mydecine announces filing of patent application for psilocybin-based MYCO-003. Pre-clinical data is showing MYCO-003 to work better than pure psilocybin.
Psychedelic medicine is the solution to the Mental Health Crisis. Psychedelic drugs are a huge commercial opportunity. Big Business moves in.
Psyched Wellness is preparing for a clinical sleep study for its proprietary extract, AME-1.
Small Pharma shows DMT to be well-tolerated and safe for the study population as it moves forward toward a Phase IIa clinical trial.
We take a closer look at each of the three psychedelics ETFs and analyze the investment objectives that each ETF addresses.
AdvisorShares' new psychedelics ETF commences trading today on the NYSE Arca Exchange (symbol "PSIL") with a focus on small-cap psychedelic stocks.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now